<code id='D678617A5D'></code><style id='D678617A5D'></style>
    • <acronym id='D678617A5D'></acronym>
      <center id='D678617A5D'><center id='D678617A5D'><tfoot id='D678617A5D'></tfoot></center><abbr id='D678617A5D'><dir id='D678617A5D'><tfoot id='D678617A5D'></tfoot><noframes id='D678617A5D'>

    • <optgroup id='D678617A5D'><strike id='D678617A5D'><sup id='D678617A5D'></sup></strike><code id='D678617A5D'></code></optgroup>
        1. <b id='D678617A5D'><label id='D678617A5D'><select id='D678617A5D'><dt id='D678617A5D'><span id='D678617A5D'></span></dt></select></label></b><u id='D678617A5D'></u>
          <i id='D678617A5D'><strike id='D678617A5D'><tt id='D678617A5D'><pre id='D678617A5D'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:leisure time    Page View:71
          People waiting in line, standing in between red rope. -- first opinion coverage from STAT
          Adobe

          Health care providers and health insurance companies are closing the books on their third quarters, and one major question continues to hang over them: How much care is everyone actually getting, now that Covid-19 isn’t scaring so many away from doctors and hospitals?

          The short answer, according to financial analysts and the companies themselves: It appears people continue to fill prescriptions, see their doctors, and get recommended surgeries.

          advertisement

          For health insurers, those trends mean they will have to deposit more money into the bank accounts of providers — perhaps more than they predicted.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          In boost for rare disease push, AstraZeneca to buy Amolyt Pharma
          In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

          AlastairGrant/APLONDON— AstraZenecasaidThursdayitwouldpurchasetheFrenchfirmAmolytPharmainadealworthu

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Medicare coverage of Wegovy, once blocked, now looks possible

          SteffenTrumpf/picturealliance/GettyImagesWASHINGTON— NovoNordisk’snewlywonpermissiontomarkettheheart